[
    [
        {
            "time": "2021-10-26",
            "original_text": "复星医药：前三季度净利润同比增长43.80%",
            "features": {
                "keywords": [
                    "复星医药",
                    "净利润",
                    "同比增长",
                    "前三季"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药：前三季度净利润同比增长43.80%",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-10-26",
            "original_text": "复星医药拟收购细菌性疫苗研制公司安特金73.01%股权",
            "features": {
                "keywords": [
                    "复星医药",
                    "收购",
                    "安特金",
                    "疫苗",
                    "股权"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药拟收购细菌性疫苗研制公司安特金73.01%股权",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-10-26",
            "original_text": "复星医药第三季度净利同比增逾40%",
            "features": {
                "keywords": [
                    "复星医药",
                    "第三季度",
                    "净利",
                    "同比增长"
                ],
                "sentiment_score": 0.88,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药第三季度净利同比增逾40%",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-10-26",
            "original_text": "复星医药拟出资参与设立星盛复盈，加强大健康产业布局",
            "features": {
                "keywords": [
                    "复星医药",
                    "出资",
                    "星盛复盈",
                    "大健康",
                    "布局"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "大健康"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药拟出资参与设立星盛复盈，加强大健康产业布局",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-10-26",
            "original_text": "加快医疗服务业务整合，复星医药子公司拟增持深圳复星健康45.19%股权",
            "features": {
                "keywords": [
                    "复星医药",
                    "医疗服务",
                    "整合",
                    "增持",
                    "股权"
                ],
                "sentiment_score": 0.82,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "医疗服务"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "加快医疗服务业务整合，复星医药子公司拟增持深圳复星健康45.19%股权",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]